Epidermal growth factor receptor: an important target in esophageal cancer

Expert Opin Ther Targets. 2013 Oct;17(10):1179-85. doi: 10.1517/14728222.2013.820709. Epub 2013 Jul 16.

Abstract

Introduction: Even after complete tumor removal by surgery, the clinical outcomes remain poor in patients with advanced esophageal cancer, justifying the need for new treatment options. Epidermal growth factor receptor (EGFR) is a molecular target for antibody-based therapy in various cancer types, and it may play important roles in the development of esophageal cancer.

Areas covered: This review evaluates the expression, function, and mechanism of EGFR in esophageal cancer and analyzes its value for the prognosis and therapy of esophageal cancer. Future developments toward the clinical applications of EGFR to cancer treatment are also envisaged.

Expert opinion: EGFR may function as an ideal therapeutic target for esophageal cancer. Further investigation of epidermal growth-factor-receptor-mediated pathways will push insight into the novel strategies of target therapy for esophageal cancer. More clinical trials should be performed to promote the success of therapeutic-clinical use of EGFR and its targets in esophageal cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism*
  • Esophageal Neoplasms / drug therapy
  • Esophageal Neoplasms / metabolism*
  • Humans
  • Molecular Targeted Therapy

Substances

  • Antineoplastic Agents
  • EGFR protein, human
  • ErbB Receptors